The lymphoma proteome

Lymphoma is a group of hematological malignancies arising from lymphocytes, primarily B cells, T cells, or natural killer (NK) cells. Lymphomas are broadly divided into Hodgkin lymphoma and non-Hodgkin lymphoma, which comprise several distinct subtypes with varying clinical characteristics and prognosis. Lymphomas often present as painless swelling of lymph nodes, sometimes together with fever, night sweats and weight loss. Hodgkin lymphoma is characterized by the presence of malignant Hodgkin and Reed–Sternberg cells, while non-Hodgkin lymphomas represent a heterogeneous group of malignancies, most commonly of B-cell origin.

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in adults. It is an aggressive malignancy characterized by the rapid proliferation of large, abnormal B lymphocytes and can arise in lymph nodes or extranodal tissues. Although DLBCL often progresses rapidly, many patients respond well to immunochemotherapy, and a substantial proportion can be cured.

Molecular characterization of lymphoma

Here, we explore the molecular characteristics of lymphoma using proteomics data from multiple sources. MS-based proteomics data are available for diffuse large B-cell lymphoma, enabling the characterization of protein expression and differences in protein abundance between tumor and non-tumor tissues. Antibody-based protein data provide additional information on protein detection and localization in tissue samples from Hodgkin and non-Hodgkin lymphomas.

Proteomics-based analysis

MS-based proteomics data from ProteinTalks-DB were used to classify proteins according to their cancer specificity and to compare paired tumor and adjacent non-tumor tissues.

The lymphoma MS-based proteome

MS-based proteomics data from ProteinTalks-DB were available from 17 patients with paired tumor and adjacent non-tumor samples of diffuse large B-cell lymphoma (in the text referred to as lymphoma). The proteomics analysis showed that 7649 of all measured proteins (n=10718) were detected in lymphoma tumors. Proteins were classified into five categories based on their relative abundance in lymphoma compared to the other analyzed cancer types, identifying proteins with elevated and cancer-specific detection.

Figure 1. The distribution of all proteins across the specificity categories (left) and distribution categories (right), based on protein abundance in lymphoma and all other analyzed cancer types.

580 proteins show some level of elevated detection in lymphoma compared to other cancers (Figure 1). The elevated category is further subdivided into three categories as shown in Table 1.

Table 1. The number of proteins in the subdivided categories of elevated detection in lymphoma.

Distribution in the 25 cancers
Detected in singleDetected in someDetected in manyDetected in all Total
Specificity
Cancer enriched 126993 147
Group enriched 033420 336
Cancer enhanced 0335212 97
Total 1263766315 580

Two examples of lymphoma-enriched proteins are shown below.


CD79A

PAX5

CD79A (CD79a molecule), a part of the B-cell antigen receptor, and PAX5 (paired box 5), a transcription factor that defines B-cell identity, are both used as diagnostic markers of B-cell lymphomas. Both are detected only in lymphoma among the analyzed cancer types, where they are classified as lymphoma enriched. Immunohistochemical staining using antibodies targeting CD79A (CAB000019) and PAX5 (HPA056394) shows strong staining in most non-Hodgkin lymphoma samples, while Hodgkin lymphoma samples show weak or no staining.

Differential protein abundance

Differences in protein abundance between tumor and adjacent non-tumor tissue were analyzed using ProteinTalks-DB. Proteins showing significantly increased or decreased abundance in lymphoma compared to adjacent non-tumor tissue are illustrated in a volcano plot below.

ProteinTalks DB relative protein data

Proteins that are significantly down- or upregulated in lymphoma compared to adjacent non-tumor tissue are illustrated in a volcano plot using data-independent acquisition mass spectrometry (DIA-MS) data from ProteinTalks-DB, based on the paired analysis of 17 tumor samples and 17 adjacent non-tumor samples from 17 patients. Proteins detected in at least 10% of the samples in both groups were tested. Proteins detected in fewer than 10% of the samples in one group were not tested, but were classified as mainly detected in tumor or mainly detected in non-tumor tissue if their detection rate was at least 50 percentage points higher in the other group.

In lymphoma, 871 and 740 proteins are down- (blue) and upregulated (red) compared to adjacent non-tumor tissue, respectively. In Table 2, the 20 most significant genes are listed.

Figure 2. Proteins highlighted in blue are significantly downregulated in cancer tissue, while those in red are significantly upregulated when compared to adjacent non-tumor tissue (|log2 fold change| ≥ 0.5 and adjusted p-value < 0.05). Gray points represent non-significant proteins. Proteins classified as mainly detected in tumor or non-tumor tissue are not shown. Paired proDA test of tumor and adjacent non-tumor samples from the same patient, with Benjamini-Hochberg adjusted p-values.

Table 2. The 20 genes with the highest significance associated with a downregulated or upregulated protein abundance in lymphoma compared to adjacent non-tumor tissue.

Gene Description Predicted location Log2 fold change Adjusted p-value Regulation
DMTN Dematin actin binding protein Intracellular -3.55 3.87e-3 Downregulated
SELENBP1 Selenium binding protein 1 Intracellular -3.11 1.39e-2 Downregulated
SLC4A1 Solute carrier family 4 member 1 (Diego blood group) Membrane -3.07 1.39e-2 Downregulated
SNCA Synuclein alpha Intracellular -2.8 1.39e-2 Downregulated
CA2 Carbonic anhydrase 2 Intracellular -2.75 1.39e-2 Downregulated
Show allShow less

Selected proteins with altered abundance in tumors

Two examples of proteins with altered abundance in tumor compared to adjacent non-tumor tissue in ProteinTalks-DB are shown below.


MS4A1 - normal tissue

MS4A1 - cancer tissue

MS4A1 (membrane spanning 4-domains A1), better known as CD20 and the target of the antibody rituximab used in lymphoma treatment, is detected in all tumor samples and in most adjacent non-tumor samples, but its protein levels are significantly higher in tumors. Immunohistochemical staining using an antibody targeting MS4A1 (CAB000015) shows strong staining in most lymphoma samples.

SELENBP1 (selenium binding protein 1), a protein expressed in many epithelial cells and in red blood cells, shows the opposite pattern. It is detected in all tumor and adjacent non-tumor samples, but its protein levels are significantly lower in tumors.

Additional information

Lymphomas comprise a heterogeneous group of malignancies arising from lymphoid cells and are broadly classified into Hodgkin and non-Hodgkin lymphomas. Non-Hodgkin lymphomas are more common and include a wide range of B-cell and T/NK-cell malignancies with varying clinical characteristics and prognosis. Risk factors include certain viral infections, immune suppression, and autoimmune diseases. Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive subtype of non-Hodgkin lymphoma, accounting for approximately 25–30% of adult cases. It is characterized by diffuse infiltration of large, atypical B lymphocytes with high proliferative activity and may arise in lymph nodes or extranodal tissues. Classification relies on histological examination, immunohistochemistry, and molecular analysis, with markers such as CD20, PAX5, CD10, BCL6, MUM1, and Ki-67 used to characterize B-cell identity and differentiation. Genetic alterations involving BCL2, BCL6, and MYC are important for identifying biologically distinct subgroups. Although DLBCL is generally aggressive, many patients respond well to immunochemotherapy, and prognosis depends on disease stage, molecular characteristics, and response to treatment.

Relevant links and publications

Yue L et al., Spatial distribution of the proteome in the human body and in cancers. Nature. (2026)
PubMed: 42310461 DOI: 10.1038/s41586-026-10660-y

Uhlén M et al., Tissue-based map of the human proteome. Science (2015)
PubMed: 25613900 DOI: 10.1126/science.1260419

Histology dictionary - Lymphoma